Lumida
/BEAM
⌘K
Beam Therapeutics Inc

Beam Therapeutics Inc

BEAM
$23.99USD-1.56%-0.38 today

MARKET CAP

2.5B

P/E (TTM)

FWD P/E

DAY RANGE

$24 – $25

52W RANGE

$20
$38

AI Summary

Stalk
TrimMedium

BEAM is exhibiting a Stage 3 distribution phase, marked by a Support Failure breakdown through key horizontal support on elevated volume. Medium-term bias remains bearish, permitting sell-side engagement, while price is extended below declining EMAs and extreme oversold readings caution against immediate selling. Execution is best deferred, stalking for a pullback into the 9/20/50 EMA and prior support zone to sell into stalled rallies. The long-term uptrend remains intact, tempering aggressive downside expectations.

  • Beam 101 Phase 1 trial reports marked HbS induction and total hemoglobin gain.
  • Ends Q2 with $1.15B cash, extending funding runway into mid-2029.
  • EPS forecast cut to $1.25 loss as development costs rise.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$51.8M$60.9M$377.7M$63.5M$139.7M
YoY %+215916.7%+17.5%+520.0%-83.2%+120.0%
P / Sales98.7x42.9x5.6x32.1x19.6x
EV / Sales100.4x49.1x5.7x33.5x19.2x
Gross Profit, Adj.$51.8M$60.9M$377.7M$63.5M$139.7M
YoY %+215916.7%+17.5%+520.0%-83.2%+120.0%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit100.4x49.1x5.7x33.5x19.2x
EBITDA, Adj.$-385.0M$-324.3M$-156.5M$-393.6M$-361.4M
YoY %-200.7%+15.8%+51.8%-151.6%+8.2%
Margin %-742.6%-532.4%-41.4%-619.7%-258.6%
EV / EBITDA-13.5x-9.2x-13.8x-5.4x-7.4x
EBIT$-392.5M$-338.5M$-176.5M$-415.6M$-383.7M
YoY %-195.6%+13.8%+47.9%-135.5%+7.7%
Margin %-757.0%-555.6%-46.7%-654.3%-274.6%
EV / EBIT-13.3x-8.8x-12.2x-5.1x-7.0x
Net Income$-370.6M$-289.1M$-132.5M$-376.7M$-80.0M
YoY %-89.2%+22.0%+54.2%-184.3%+78.8%
Net Margin-714.9%-474.5%-35.1%-593.1%-57.2%
EPS (GAAP)-$5.77-$4.13-$1.72-$4.58-$0.81
YoY %-37.7%+28.4%+58.4%-166.3%+82.3%